Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

<p>Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.</p>